Roche Holding Ltd(RHHBY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

RHHBY Roche Holding Ltd

Pre-Market Trading 11-21 16:00:00 EST Delay

盘前35.29

+0.000.00%

08:00 EST

{"stockData":{"symbol":"RHHBY","market":"US","secType":"STK","nameCN":"Roche Holding Ltd","latestPrice":35.29,"timestamp":1732222800000,"preClose":35.13,"halted":0,"volume":1461250,"hourTrading":{"tag":"盘前","latestPrice":35.29,"preClose":35.29,"latestTime":"08:00 EST","volume":2,"amount":70.58,"timestamp":1732280411348},"delay":15,"floatShares":6374000000,"shares":6474029800,"eps":1.550894,"marketStatus":"Pre-Market Trading","change":0.16,"latestTime":"11-21 16:00:00 EST Delay","open":35.4,"high":35.5,"low":35.23,"amount":51645240.563000016,"amplitude":0.007686,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":1.550894,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1732285800000},"marketStatusCode":1,"adr":0,"adrRate":0.125,"exchange":"OTCQX","adjPreClose":35.29,"volumeRatio":1.3144628786286454},"requestUrl":"/m/hq/s/RHHBY","defaultTab":"news","newsList":[{"id":"2485268014","title":"Weight-Loss Drugs Don't Seem To Impress RFK Jr. Should Eli Lilly, Novo Nordisk Investors Worry?","url":"https://stock-news.laohu8.com/highlight/detail?id=2485268014","media":"Blockhead","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485268014?lang=en_us&edition=fundamental","pubTime":"2024-11-22 21:00","pubTimestamp":1732280425,"startTime":"0","endTime":"0","summary":"Robert F. Kennedy Jr.'s potential appointment to HHS has spooked Eli Lilly stock and stocks tied to popular weight-loss drugs.","market":"nz","thumbnail":"https://www.investors.com/wp-content/uploads/2021/03/Stock-Lilly-HQ9-shutt-150x150.jpg","type":0,"news_type":0,"thumbnails":["https://www.investors.com/wp-content/uploads/2021/03/Stock-Lilly-HQ9-shutt-150x150.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.investors.com/news/technology/eli-lilly-stock-rfk-jr-weight-loss-drugs-glp-1-drugs/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investor_business_daily_highlight","symbols":["LU0096364046.USD","PFE.AU","LU2324357040.USD","LU0882574055.USD","LU0417517546.SGD","LU2106854487.HKD","LU0061475181.USD","LLY","IE00BLSP4452.SGD","LU1868836591.USD","IE00BK4W5M84.HKD","IE00BFTCPJ56.SGD","LU1069344957.HKD","LU1868836914.USD","LU1023059063.AUD","NVO.AU","BK4211","SGXZ81514606.USD","SGXZ99366536.SGD","AMGN","GPCR","SG9999001176.SGD","RHHBY","BK7095","LU2112291526.USD","LU1066053197.SGD","LU1868837136.USD","IE00B19Z3581.USD","LU2361044865.SGD","ISBC","IE0004445239.USD","03165","NVO","LU0097036916.USD","LU2242652126.USD","LU1035775433.USD","LU0203201768.USD","LU0079474960.USD","LU0114720955.EUR","LU0320765059.SGD","LU0256863811.USD","VKTX","PFE","SGXZ51526630.SGD","BK4139","BK4581","LU0122379950.USD","LU0820561818.USD","SG9999001176.USD","LU0943347566.SGD"],"gpt_icon":1},{"id":"2484760720","title":"Nvidia Says BioNeMo Framework Will Advance Drug Discovery","url":"https://stock-news.laohu8.com/highlight/detail?id=2484760720","media":"Dow Jones","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484760720?lang=en_us&edition=fundamental","pubTime":"2024-11-19 03:11","pubTimestamp":1731957060,"startTime":"0","endTime":"0","summary":"Nvidia said companies across industries are adopting its open-source BioNeMo framework, which offers computing tools designed to help artificial intelligence advance drug discovery and accelerate molecule design.These companies, from sectors including pharma, biotech and academia, include Argonne National Laboratory, Roche Group's Genentech and Weights & Biases, the tech company said Monday. More than 200 users have integrated the framework into their workflows.The framework uses accelerated computing infrastructure to reduce costs, increase scale and speed up drug discovery workflows by providing insights from biomolecular data, the company said.Vice President of healthcare Kimberly Powell said recent Nobel Prize wins in chemistry demonstrate AI and advanced computing ability to contribute to the pharmaceutical industry. \"To help unravel the complexities of biological systems, we've introduced the open-source BioNeMo Framework, which will enable researchers world-wide to accelerate th","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"9b91bc36a41ca6f2915504b9e6e5cc51","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2433249047.HKD","NVDX","LU0234570918.USD","IE00B19Z9505.USD","NVDS.UK","LU1066053197.SGD","NVD3.UK","LU0276348264.USD","LU2237438978.USD","IE00B775H168.HKD","LU0348723411.USD","BK4141","LU2417539215.USD","LU2552382058.USD","2NVD.UK","NVDA","LU1496350502.SGD","IE00BDCRKT87.USD","IE0009356076.USD","LU0203202063.USD","LU0882574139.USD","LU1674673428.USD","LU1064131342.USD","03165","LU2237957902.USD","NVDY","BK4581","LU0689472784.USD","LU2552382132.HKD","LU2361045086.USD","LU2125909247.SGD","LU1623119135.USD","NVDU","LU2294711713.HKD","LU1069344957.HKD","LU0889565833.HKD","LU1861215975.USD","RHHBY","SG9999014542.SGD","NVD","SGXZ81514606.USD","SNVD.UK","NVD2.UK","3NVD.UK","LU0124676726.USD","NVDD","NVDS","LU1280957306.USD","LU0943347566.SGD"],"gpt_icon":1},{"id":"2484647306","title":"Roche receives CE Mark for Ventana FOLR1 RxDx Assay","url":"https://stock-news.laohu8.com/highlight/detail?id=2484647306","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484647306?lang=en_us&edition=fundamental","pubTime":"2024-11-18 18:30","pubTimestamp":1731925847,"startTime":"0","endTime":"0","summary":"Roche (RHHBY) announced that it has received CE Mark for its Ventana FOLR1 RxDx Assay. This is the first immunohistochemistry, or IHC, companion di...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/roche-receives-ce-mark-for-ventana-folr1-rxdx-assay?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/roche-receives-ce-mark-for-ventana-folr1-rxdx-assay?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RHHBY","BK4007","BK4109","CE","BK4585","BK4588","03165"],"gpt_icon":0},{"id":"2484690209","title":"Roche receives CE Mark for VENTANA FOLR1 (FOLR1-2.1) RxDx Assay as the first IHC-based companion diagnostic to identify ovarian cancer patients eligible for ELAHERE","url":"https://stock-news.laohu8.com/highlight/detail?id=2484690209","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484690209?lang=en_us&edition=fundamental","pubTime":"2024-11-18 14:00","pubTimestamp":1731909600,"startTime":"0","endTime":"0","summary":"The VENTANA FOLR1  RxDx Assay detects the folate receptor 1 protein , which is over-expressed in most ovarian cancers.The test identifies ovarian cancer patients eligible for targeted treatment with ELAHERE.This certification follows the unprecedented decision by regulators to grant an early exemption approval for the test in Germany and Austria earlier this year.Ovarian cancer is the eighth overall cause for cancer death in women worldwide, representing 4.7% of all cancer deaths in women. It is also one of the deadliest gynaecological cancers worldwide. In 2022, 46,232 women in Europe and 209,596 women worldwide died from ovarian cancer.5. The launch of Roche's first IHC companion test for ovarian cancer in CE countries highlights the company's commitment, as the world's leading provider of in vitro diagnostics, to continued innovation and evolution of its products in order to advance personalised healthcare and deliver novel, high medical value solutions that improve patients' lives.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/FEw8mECWg0tyUzAvLMKHOg--~B/aD0yMDg7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/14cfd9b980421a2a2b79b6c4cbbb02d5","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/FEw8mECWg0tyUzAvLMKHOg--~B/aD0yMDg7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/14cfd9b980421a2a2b79b6c4cbbb02d5"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/roche-receives-ce-mark-ventana-060000396.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/roche-receives-ce-mark-ventana-060000396.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","CE","BK4162","BK4080","03165","ADC","BK4109","IHC","BK4148","BK4231","BK4585","ROG","RHHBY","BK4007"],"gpt_icon":0},{"id":"2483384665","title":"Roche Holding AG Falls Thursday, Underperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2483384665","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483384665?lang=en_us&edition=fundamental","pubTime":"2024-11-15 01:16","pubTimestamp":1731604560,"startTime":"0","endTime":"0","summary":"This article was automatically generated using Dow Jones technology.Shares of Roche Holding AG  dropped 0.6% to CHF261.60 Thursday on what proved to be an overall favorable trading session for the stock market, with the Swiss SMI Index  rising 0.7% to 11,783.65.Roche Holding AG closed CHF26.60 short of its 52-week high of CHF288.20, which the company achieved on September 2, 2024.Trading volume was 1,397,149, compared to the 50-day average trading volume of 1,214,263.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AG","RHHBY"],"gpt_icon":0},{"id":"2483703936","title":"Roche Holding AG Falls Tuesday, Outperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2483703936","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483703936?lang=en_us&edition=fundamental","pubTime":"2024-11-13 01:16","pubTimestamp":1731431760,"startTime":"0","endTime":"0","summary":"This article was automatically generated using Dow Jones technology.Shares of Roche Holding AG  slid 1.1% to CHF262.50 Tuesday on what proved to be an overall negative trading session for the stock market, with the Swiss SMI Index  falling 1.6% to 11,712.09.Roche Holding AG closed CHF25.70 below its 52-week high of CHF288.20, which the company achieved on September 2, 2024.Trading volume was 1,803,582, compared to the 50-day average trading volume of 1,240,773.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AG","RHHBY"],"gpt_icon":0},{"id":"2481448396","title":"Genentech terminates agreement for Nykode cancer vaccine program","url":"https://stock-news.laohu8.com/highlight/detail?id=2481448396","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481448396?lang=en_us&edition=fundamental","pubTime":"2024-11-08 23:45","pubTimestamp":1731080742,"startTime":"0","endTime":"0","summary":"Nykode Therapeutics (VACBF) announced last night that it has received notification from Genentech, a member of the Roche (RHHBY), of its decision t...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/genentech-terminates-agreement-for-nykode-cancer-vaccine-program?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/genentech-terminates-agreement-for-nykode-cancer-vaccine-program?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4007","VACBF","03165","RHHBY"],"gpt_icon":0},{"id":"2481369771","title":"Roche Holding AG Rises Thursday","url":"https://stock-news.laohu8.com/highlight/detail?id=2481369771","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481369771?lang=en_us&edition=fundamental","pubTime":"2024-11-08 01:16","pubTimestamp":1730999760,"startTime":"0","endTime":"0","summary":"This article was automatically generated using Dow Jones technology.Shares of Roche Holding AG  rose 0.6% to CHF265.80 Thursday on what proved to be an overall positive trading session for the stock market, with the Swiss SMI Index  rising 0.6% to 11,917.00.The stock's rise snapped a three-day losing streak.Roche Holding AG closed CHF22.40 short of its 52-week high of CHF288.20, which the company reached on September 2, 2024.Trading volume was 993,451, compared to the 50-day average trading volume of 1,268,159.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AG","RHHBY","BK4210","03165","BK4007"],"gpt_icon":0},{"id":"2481616742","title":"RHHBY or ABBV: Which Is the Better Value Stock Right Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2481616742","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481616742?lang=en_us&edition=fundamental","pubTime":"2024-11-08 00:40","pubTimestamp":1730997613,"startTime":"0","endTime":"0","summary":"Investors looking for stocks in the Large Cap Pharmaceuticals sector might want to consider either Roche Holding AG  or AbbVie . But which of these two stocks offers value investors a better bang for their buck right now?The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The Zacks Rank favors stocks with strong earnings estimate revision trends, and our Style Scores highlight companies with specific traits.Right now, Roche Holding AG is sporting a Zacks Rank of #2 , while AbbVie has a Zacks Rank of #3 . This means that RHHBY's earnings estimate revision activity has been more impressive, so investors should feel comfortable with its improving analyst outlook. But this is only part of the picture for value investors.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/XxozWWpdDFgGg6m0CzltLg--~B/aD02MDI7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/45c083e4721b0d0d1f6e431ec0bb5cc1","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/XxozWWpdDFgGg6m0CzltLg--~B/aD02MDI7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/45c083e4721b0d0d1f6e431ec0bb5cc1"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/rhhby-abbv-better-value-stock-164013909.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4566","IE00BFTCPJ56.SGD","LU0965509283.SGD","LU0417517546.SGD","LU0738911758.USD","ABBV","IE00B42XCP33.USD","RHHBY","BK4559","LU0114720955.EUR","LU0545039389.USD","BK4550","LU0708994859.HKD","LU0985320562.USD","LU0211328371.USD","LU0158827948.USD","IE00BJJMRZ35.SGD","LU0211327993.USD","LU0965509101.SGD","LU1003077747.HKD","BK4581","LU0203347892.USD","LU0203345920.USD","IE00B4R5TH58.HKD","03165","LU1023059063.AUD","IE00BGHQF631.EUR","LU0965508806.USD","IE00BDGV0183.EUR","LU0234572021.USD","LU0795875169.SGD","LU0170899867.USD","IE00B3PB1722.GBP","LU0234570918.USD","LU0949170772.SGD","IE0002141913.USD","BK4139","BK4585","BK4533","IE00BSNM7G36.USD","BK4588","LU0256863902.USD","LU0256863811.USD","LU0820561818.USD","IE00BVYPNV92.GBP","LU0965509010.AUD","LU0553294199.USD","BK4534","LU0198837287.USD","LU0912757837.SGD"],"gpt_icon":0},{"id":"2481550348","title":"Roche downgraded to Hold from Buy at Erste Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2481550348","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481550348?lang=en_us&edition=fundamental","pubTime":"2024-11-05 20:36","pubTimestamp":1730810197,"startTime":"0","endTime":"0","summary":"Erste Group analyst Hans Engel downgraded Roche (RHHBY) to Hold from Buy. Published first on TheFly – the ultimate source for real-time, market-mov...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/roche-downgraded-to-hold-from-buy-at-erste-group?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/roche-downgraded-to-hold-from-buy-at-erste-group?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","RHHBY","03165"],"gpt_icon":0},{"id":"2480506004","title":"Roche's Antibody Against Alzheimer's Looks the Best Yet -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2480506004","media":"Dow Jones","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480506004?lang=en_us&edition=fundamental","pubTime":"2024-11-01 05:31","pubTimestamp":1730410260,"startTime":"0","endTime":"0","summary":"Roche Holding has one of the most promising treatments for Alzheimer's in clinical trials. The drug is several years away from reaching the market, however.Amid a Madrid conference for Alzheimer's researchers, Roche scientists talked to investors about the company's experimental diagnostics and drugs for the devastating brain disease -- including trontinemab, the first anti-Alzheimer's antibody that easily crosses the blood-brain barrier.Roche plans to start pivotal Phase 3 trials of the drug next year. They wouldn't be complete until 2028.\"The blood-brain barrier has been the Holy Grail of neuroscience therapeutics,\" said Azad Bonni, who heads Roche's neuroscience drug development. In a Phase 2 study of 160 patients, trontinemab has practically cleared most patients' brain cells of the deadly amyloid plaque that accumulates in Alzheimer's.Today, Alzheimer's patients are diagnosed and monitored with brain imaging techniques, like a PET scan, or with a spinal tap. Roche is developing si","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0820561818.USD","03165","LU0114720955.EUR","IE00BJJMRZ35.SGD","IE00BK4W5L77.USD","IE00BJLML261.HKD","LU0689472784.USD","LU0943347566.SGD","BK4588","IE0004445239.USD","BK4532","LU1035775433.USD","IE0002141913.USD","IE00BK4W5M84.HKD","LU0094547139.USD","LU0256863811.USD","BK4533","BK4139","LU1064131342.USD","LU0058720904.USD","IE00B19Z9Z06.USD","IE00B2B36J28.USD","LU0234570918.USD","LU0320765059.SGD","LU0096364046.USD","LU0882574139.USD","BIIB","LU1061106388.HKD","LU0889565916.HKD","IE0009355771.USD","LU0320765992.SGD","RHHBY","LU0672654240.SGD","LU0385154629.USD","LU0106261372.USD","IE00B894F039.SGD","LU1023059063.AUD","LU1093756168.USD","IE00BFTCPJ56.SGD","LU0466842654.USD","LU0354030438.USD","LU0471298777.SGD","LU0708995401.HKD","LU0256863902.USD","LU0289739699.SGD","LU0471298694.HKD","LU1057294990.SGD","LU0882574055.USD","BK4585"],"gpt_icon":1},{"id":"2479705665","title":"Roche announces phase III INAVO120 results were published","url":"https://stock-news.laohu8.com/highlight/detail?id=2479705665","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479705665?lang=en_us&edition=fundamental","pubTime":"2024-10-31 18:26","pubTimestamp":1730370368,"startTime":"0","endTime":"0","summary":"Roche (RHHBY) announced that a detailed analysis of the positive phase III INAVO120 results, evaluating Itovebi in combination with palbociclib and...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/roche-announces-phase-iii-inavo120-results-were-published?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/roche-announces-phase-iii-inavo120-results-were-published?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["03165","RHHBY","BK4134","BK4007","III"],"gpt_icon":0},{"id":"2479416263","title":"AbbVie's Deal for Alzheimer's Antibody Raises Curtain for Roche News on Wednesday -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2479416263","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479416263?lang=en_us&edition=fundamental","pubTime":"2024-10-30 05:31","pubTimestamp":1730237460,"startTime":"0","endTime":"0","summary":"Hopes are rising for better ways to deal with Alzheimer's disease.Late Monday, AbbVie announced an agreement to buy a firm that is testing a more effective way of battling the illness. AbbVie is spending $1.4 billion for Aliada, a start-up that is in Phase 1 testing of an antibody that can penetrate the blood-brain barrier better than approved Alzheimer's drugs like Eli Lilly's Kisunla or the Esai/ Biogen product Leqembi.That transaction, seen as a vote of confidence, has put the focus on other drug firms testing similar barrier-bridging antibodies. Chief among them is Roche Holding: Wednesday morning it will report interim Phase 2 results for its antibody trontinemab, which promises to be the best Alzheimer's treatment so far.This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journa","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0965509283.SGD","LU0211328371.USD","IE00BK4W5M84.HKD","LU0820561818.USD","RHHBY","LU0385154629.USD","LU0097036916.USD","IE00BFTCPJ56.SGD","IE00BVYPNV92.GBP","LU0198837287.USD","IE0004445239.USD","IE00B1BXHZ80.USD","LU0471298777.SGD","DNLI","IE00BJLML261.HKD","IE00B3PB1722.GBP","BK4559","LU0965509101.SGD","LU0912757837.SGD","LU1064131342.USD","ABBV","IE00B42XCP33.USD","IE00BJJMRZ35.SGD","LU0985320562.USD","VYGR","LU0234570918.USD","LU0354030438.USD","LU0965508806.USD","GB00BDT5M118.USD","LU0965509010.AUD","LU1061106388.HKD","LU0203201768.USD","03165","LU0640476718.USD","BK4581","IE00B2B36J28.USD","LU0882574139.USD","LU1023059063.AUD","IE00BGHQF631.EUR","LU0122379950.USD","LU0203347892.USD","LU0114720955.EUR","BK4516","LU0456855351.SGD","LU0310799852.SGD","IE0009355771.USD","LU0354030511.USD","LU1069344957.HKD","LU0861579265.USD"],"gpt_icon":1},{"id":"2478614812","title":"Roche: Currency Headwinds Are Masking Strong Growth Trends","url":"https://stock-news.laohu8.com/highlight/detail?id=2478614812","media":"seekingalpha","labels":["analysis"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478614812?lang=en_us&edition=fundamental","pubTime":"2024-10-28 09:35","pubTimestamp":1730079342,"startTime":"0","endTime":"0","summary":"Roche's strong year-to-date results are masked by the strength of the Swiss franc and are also impacted by declining COVID-19 sales, but underlying growth trends are strong.Key products like Vabysmo, ","market":"us","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2070915153/image_2070915153.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2070915153/image_2070915153.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4730004-roche-currency-headwinds-are-masking-strong-growth-trends","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"analysis","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["03165","RHHVF","BK4007","RHHBF","RHHBY"],"gpt_icon":0},{"id":"2478296142","title":"Pharma Stock Roundup: RHHBY Earnings, Drug Pipeline & Regulatory News","url":"https://stock-news.laohu8.com/highlight/detail?id=2478296142","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478296142?lang=en_us&edition=fundamental","pubTime":"2024-10-26 03:00","pubTimestamp":1729882800,"startTime":"0","endTime":"0","summary":"This week, Roche RHHBY announced its third-quarter and nine-month results. Sanofi SNY confirmed that it is holding exclusive talks with U.S. private equity company CD&R to sell a controlling stake in its consumer healthcare  business, Opella.The FDA approved Pfizer’s PFE respiratory syncytial virusAbrysvo for adults under the age of 60. Novo Nordisk’s NVO cardiovascular outcomesstudy on its popular drug, oral semaglutide, met its primary endpoint. The Committee for Medicinal Products for Human Use  of the European Medicines Agency  recommended approval of AstraZeneca’s AZN Wainzua in the EU.Here's a recap of the week’s most important stories.Roche’s performance in the third quarter and the first nine months of 2024 was strong, driven by high demand for its drugs and diagnostic tests. Roche’s sales rose 9% at a constant exchange rate  in the third quarter.FDA Approves Pfizer’s RSV Jab, Abrysvo for Younger Adults. Abrysvo becomes the only RSV vaccine approved for adults younger than 50. ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/VTpWEp9iphTX3xsYcMogbg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ca9d72216d7bb42fc496430c3df29b41","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/VTpWEp9iphTX3xsYcMogbg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ca9d72216d7bb42fc496430c3df29b41"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pharma-stock-roundup-rhhby-earnings-190000293.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["RHHBY","SNY","AZN","NVO"],"gpt_icon":0},{"id":"2478652502","title":"CTLT Stock Falls as Potential Hindrance to NVO Buyout Deal Increases","url":"https://stock-news.laohu8.com/highlight/detail?id=2478652502","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478652502?lang=en_us&edition=fundamental","pubTime":"2024-10-24 23:10","pubTimestamp":1729782600,"startTime":"0","endTime":"0","summary":"Shares of Catalent CTLT lost 0.9% on Oct. 23 with the rise in uncertainty related to its acquisition by Novo Holding following a report from Reuters on opposition from several large pharma companies as well as an alliance of U.S. consumer, patient and workers advocacy groups.CTLT and Novo Holdings, the parent company of Novo Nordisk NVO, entered into a merger agreement in February. Per the agreement, NVO’s parent company will acquire all outstanding shares of Catalent for $63.50 per share in cash. The deal values Catalent at $16.5 billion on an enterprise value basis. As part of the deal, Novo Nordisk will acquire three of Catalent’s fill-finish sites from Novo Holdings for $11 billion, which will support the manufacturing capacity at scale and speed for Novo Nordisk’s diabetes and obesity treatments.The shares lost as these oppositions may cause hindrances for the deal, which, in turn, can hurt CTLT’s short-term prospects. CTLT’s shares have gained 32.2% so far this year against the i","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/y6swp5qnudxxN4rNeiZSRA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/34fbd46b67540f3cdb50013c4a171555","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/y6swp5qnudxxN4rNeiZSRA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/34fbd46b67540f3cdb50013c4a171555"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ctlt-stock-falls-potential-hindrance-151000502.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B19Z3B42.SGD","IE00BK4W5M84.HKD","IE0009355771.USD","IE00B1BXHZ80.USD","LU0203202063.USD","FTC","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","LU0321505868.SGD","LU0256863902.USD","LU0689472784.USD","BK4581","LU0417517546.SGD","IE00BZ1G4Q59.USD","LU0170899867.USD","BK4534","LU1035775433.USD","SG9999013999.USD","LU0456855351.SGD","LU0354030511.USD","LU1057294990.SGD","LU1093756325.SGD","NVO","LU0820561818.USD","RHHBY","LU0114720955.EUR","LU0466842654.USD","GB00BDT5M118.USD","LU0943347566.SGD","SG9999003800.SGD","BK4588","LU0289739699.SGD","LU1061106388.HKD","IE00B2B36J28.USD","CTLT","LU0097036916.USD","LU1894683264.USD","03165","LU0058720904.USD","LU1066053197.SGD","BK4516","LLY","LU0109391861.USD","LU0061475181.USD","LU0708995401.HKD","BK4530","LU0154236417.USD","IE00B4R5TH58.HKD","LU0320765059.SGD"],"gpt_icon":1},{"id":"2477017534","title":"Roche CEO says antitrust regulators should block Catalent sale to Novo Foundation","url":"https://stock-news.laohu8.com/highlight/detail?id=2477017534","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477017534?lang=en_us&edition=fundamental","pubTime":"2024-10-23 22:58","pubTimestamp":1729695522,"startTime":"0","endTime":"0","summary":"Carolina Rudah The CEO of Swiss pharmaceuticals behemoth Roche (OTCQX:RHHBY) said he believes antitrust regulators should not allow Novo Nordisk Foundation's to purchase Catalent (NYSE:CTLT).  \"It's not a problem for us, but it could be a problem for other smaller players, if there is a","market":"other","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2112991930/image_2112991930.jpg?io=getty-c-w750","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2112991930/image_2112991930.jpg?io=getty-c-w750"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4195690-roche-ceo-says-antitrust-regulators-should-block-catalent-sale-to-novo-foundation","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha_trending_news","symbols":["BK4588","BK4007","BK4585","RHHBY","03165","CTLT","BK4530"],"gpt_icon":0},{"id":"2477555436","title":"Roche Retains Outlook After Two Out Of Three Big Hitters Top Sales Expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2477555436","media":"Blockhead","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477555436?lang=en_us&edition=fundamental","pubTime":"2024-10-23 21:05","pubTimestamp":1729688752,"startTime":"0","endTime":"0","summary":"Roche stock was unmoved early Wednesday after the pharma giant reported light third-quarter sales but kept its 2024 outlook.","market":"nz","thumbnail":"https://www.investors.com/wp-content/uploads/2017/12/stock-Roche-04-company-150x150.jpg","type":0,"news_type":0,"thumbnails":["https://www.investors.com/wp-content/uploads/2017/12/stock-Roche-04-company-150x150.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.investors.com/news/technology/roche-stock-roche-earnings-q3-2024/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investor_business_daily_highlight","symbols":["BK4007","03165","RHHBY"],"gpt_icon":1},{"id":"2477880485","title":"Roche reaffirms 2024 outlook after Q3 beat","url":"https://stock-news.laohu8.com/highlight/detail?id=2477880485","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477880485?lang=en_us&edition=fundamental","pubTime":"2024-10-23 19:07","pubTimestamp":1729681648,"startTime":"0","endTime":"0","summary":"Michael Vi/iStock Editorial via Getty ImagesSwiss Pharmaceutical giant Roche Holding   on Wednesday reaffirmed its full-year sales and earnings outlook after the company’s third-quarter sales results exceeded forecasts. The Basel-based company reported CHF15.1B  in sales for Q3, indicating ~9% YoY growth on a currency-adjusted basis and surpassing Street","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1181551537/image_1181551537.jpg?io=getty-c-w750","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1181551537/image_1181551537.jpg?io=getty-c-w750"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4193888-roche-reaffirms-2024-outlook-after-q-3-beat","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha_trending_news","symbols":["RHHBF","BK4007","RHHBY","03165"],"gpt_icon":0},{"id":"2477307825","title":"Roche sees 2024 core EPS growing in high single digit range","url":"https://stock-news.laohu8.com/highlight/detail?id=2477307825","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477307825?lang=en_us&edition=fundamental","pubTime":"2024-10-23 18:50","pubTimestamp":1729680610,"startTime":"0","endTime":"0","summary":"Roche (RHHBY) expects an increase in Group sales in the mid single digit range. Core earnings per share are targeted to grow in the high single dig...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/roche-sees-2024-core-eps-growing-in-high-single-digit-range-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/roche-sees-2024-core-eps-growing-in-high-single-digit-range-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["03165","BK4007","RHHBY"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.roche.com","stockEarnings":[{"period":"1week","weight":-0.0006},{"period":"1month","weight":0.0654},{"period":"3month","weight":0.0843},{"period":"6month","weight":0.0925},{"period":"1year","weight":0.22},{"period":"ytd","weight":0.1631}],"description":"Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.","exchange":"OTCQX","name":"Roche Holding Ltd","nameEN":"Roche Holding Ltd"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Roche Holding Ltd(RHHBY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Roche Holding Ltd(RHHBY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Roche Holding Ltd,RHHBY,Roche Holding Ltd股票,Roche Holding Ltd股票老虎,Roche Holding Ltd股票老虎国际,Roche Holding Ltd行情,Roche Holding Ltd股票行情,Roche Holding Ltd股价,Roche Holding Ltd股市,Roche Holding Ltd股票价格,Roche Holding Ltd股票交易,Roche Holding Ltd股票购买,Roche Holding Ltd股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Roche Holding Ltd(RHHBY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Roche Holding Ltd(RHHBY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction